, GlobeNewswire
Addex to Present Progress on Multiple Allosteric Modulator Programs for Neurodegenerative and other Neurological Disorders
Addex Pharmaceuticals /
Addex to Present Progress on Multiple Allosteric Modulator Programs for
Neurodegenerative and other Neurological Disorders
. Verarbeitet und übermittelt durch Thomson Reuters ONE.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
Six Presentations at the 7th International Meeting on Metabotropic Glutamate
Receptors
Geneva, Switzerland, October 3, 2011 - Addex Pharmaceuticals (SIX:ADXN), a
leading biopharmaceutical company pioneering allosteric modulation-based drug
discovery and development, announced today that its scientists will present data
on multiple metabotropic glutamate receptor (mGluR) allosteric modulator
programs, including small molecule modulators of mGluR subtypes 2, 4, 5 and 7.
Held every three years, the prestigious International Meeting on Metabotropic
Glutamate Receptors, in Italy, brings together the world's leading researchers
in this field.
"These six presentations represent our continued success in addressing the
elusive mGluR targets and re-affirm our leadership position in addressing
important previously undruggable targets with oral small molecule allosteric
modulators," said Bharatt Chowrira, CEO of Addex. "Our advances in this field
are further illustrated by two lead products targeting mGluR5 and mGluR2,
dipraglurant-IR for Parkinson's disease levodopa-induced dyskinesia (PD-LID) and
ADX71149 for schizophrenia, respectively; both are currently in mid-stage
clinical testing and each has the potential to be first-in-class and best-in-
class in treating these serious neurological disorders."
Dipraglurant-IR, is an mGluR5 negative allosteric modulator, or NAM, which is in
Phase IIa testing for PD-LID. Top-line data are expected to be reported in the
first half of 2012. Addex partner Janssen Pharmaceuticals Inc. is developing
ADX71149, an mGluR2 positive allosteric modulator, or PAM, currently in Phase
IIa testing for the treatment of schizophrenia.
Glutamate, like dopamine and serotonin, is one of the major neurotransmitters in
the brain and other parts of the central nervous system. Because of their
importance, each of the many glutamate-specific receptors, including all eight
subtypes of mGluRs, has been the subject of intense research and drug discovery
efforts for more than 20 years. But, despite ever increasing knowledge about
their role in various neurologic disorders, the industry has struggled to
identify compounds that can selectively differentiate between the various
glutamate receptor subtypes using conventional small molecule discovery
techniques. In contrast, allosteric modulators have achieved excellent
selectivity for each mGluR subtype. This is because the allosteric binding sites
are less conserved compared to the receptor's active site, which is the binding
site for the body's natural activators (i.e. endogenous ligands) and
conventional small molecule drugs.
"At Addex, we have developed a proprietary allostery-biased library and highly
sensitive HTS screening systems tailored for discovery of selective and potent
allosteric modulators. In short, by industrializing the process of discovering
allosteric modulators, we are addressing an important bottleneck in small
molecule drug discovery that has hindered drug developers for decades and has
resulted in a growing number of undruggable validated targets," said Dr. Sonia
Poli, Head of CNS and Non-Clinical Development at Addex. "We believe these
orally bioavailable small molecules are able to exert exquisite selectivity at
the receptor subtype level and have the potential to be optimized into drugs
with the fine-tuned control needed to address major CNS disorders such as
schizophrenia, Parkinson's and Alzheimer's diseases, as well as non-CNS
indications."
Oral Presentations
Thursday, October 6, 4.30 - 4.55 pm
Selective mGluR2 negative allosteric modulators for the treatment of cognitive
deficits associated with Alzheimer's disease
Friday, October 7, 10.05 - 10.30 am
Anti-parkinsonian and anti-dyskinetic effects of dipraglurant (ADX48621), a
novel mGluR5 negative allosteric modulator in clinical development
Friday, October 7, 1.25 - 1.50 pm
Novel metabotropic glutamate receptor 4 (mGluR4) allosteric potentiators for the
treatment of Parkinson's disease and anxiety
Poster Presentations
Wednesday, October 5 from 20.00 to 23.00 in the Pharmacology session
Discovery and characterization of novel metabotropic glutamate receptor 4
(mGluR4) allosteric potentiators
Wednesday, October 5 from 20.00 to 23.00 in the Pharmacology session
Identification, synthesis and SAR investigation of a series of novel
metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators
Wednesday, October 5 from 20.00 to 23.00 in the Psychiatric Disorders session
Development of novel metabotropic glutamate receptor 7 (mGluR7) negative
allosteric modulators for treatment of anxiety disorders
Addex Pharmaceuticals (www.addexpharma.com) discovers and develops an emerging
class of small molecule drugs, called allosteric modulators, which have the
potential to be more specific and confer significant therapeutic advantages over
conventional "orthosteric" small molecule or biological drugs. The Company uses
its proprietary discovery platform to address receptors and other proteins that
are recognized as attractive targets for modulation of important diseases with
unmet medical needs. The Company's two lead products are being investigated in
Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative
allosteric modulator or NAM) is being developed by Addex to treat Parkinson's
disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive
allosteric modulator or PAM) is being developed by our partner Janssen
Pharmaceuticals, Inc., to treat schizophrenia. Addex also is advancing several
preclinical programs including: GABA-BR PAM for pain, overactive bladder and
other disorders; mGluR4 PAM for Parkinson's, anxiety and other diseases; GLP1R
PAM for type 2 diabetes; mGluR2 NAM for treating Alzheimer's disease and
depression; and FSHR/LHR NAM for sex hormone dependent tumors & reproductive
system disorders. In addition, Addex has discovery programs to identify
allosteric modulators of: receptor tyrosine kinase (RTK) superfamily, including
TrkB PAM for treating neurodegenerative diseases (e.g. Alzheimer's, Parkinson's
and Huntington's diseases); and TNF receptor superfamily, including TNFR1 NAM
for inflammation (e.g. rheumatoid arthritis) and other diseases.
Chris Maggos
Business Development & Communication
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos(at)addexpharma.com
Disclaimer: The foregoing release may contain forward-looking statements that
can be identified by terminology such as "not approvable", "continue",
"believes", "believe", "will", "remained open to exploring", "would", "could",
or similar expressions, or by express or implied discussions regarding Addex
Pharmaceuticals Ltd, its business, the potential approval of its products by
regulatory authorities, or regarding potential future revenues from such
products. Such forward-looking statements reflect the current views of Addex
Pharmaceuticals Ltd regarding future events, future economic performance or
prospects, and, by their very nature, involve inherent risks and uncertainties,
both general and specific, whether known or unknown, and/or any other factor
that may materially differ from the plans, objectives, expectations, estimates
and intentions expressed or implied in such forward-looking statements. Such may
in particular cause actual results with allosteric modulators of mGluR2,
mGluR4,mGluR5, GABABR, FSHR/LHR, GLP1R, TNFR1, RTK, TrkB or other therapeutic
targets to be materially different from any future results, performance or
achievements expressed or implied by such statements. There can be no guarantee
that allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR, FSHR/LHR, GLP1R,
TNFR1, RTK, TrkB or other therapeutics targets will be approved for sale in any
market or by any regulatory authority. Nor can there be any guarantee that
allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR, FSHR/LHR, GLP1R,
TNFR1, RTK, TrkB or other therapeutic targets will achieve any particular levels
of revenue (if any) in the future. In particular, management's expectations
regarding allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR, FSHR/LHR,
GLP1R, TNFR1, RTK, TrkB or other therapeutic targets could be affected by, among
other things, unexpected actions by our partners, unexpected regulatory actions
or delays or government regulation generally; unexpected clinical trial results,
including unexpected new clinical data and unexpected additional analysis of
existing clinical data; competition in general; government, industry and general
public pricing pressures; the company's ability to obtain or maintain patent or
other proprietary intellectual property protection. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those anticipated, believed,
estimated or expected. Addex Pharmaceuticals Ltd is providing the information in
this press release as of this date and does not undertake any obligation to
update any forward-looking statements contained in this press release as a
result of new information, future events or otherwise, except as may be required
by applicable laws.
--- Ende der Mitteilung ---
Addex Pharmaceuticals
12, chemin des Aulx Plan-les-Ouates; Geneva Schweiz
ISIN: CH0029850754;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Addex Pharmaceuticals via Thomson Reuters ONE
[HUG#1551607]
Addex to Present Progress on Multiple Allosteric Modulator Programs for
Neurodegenerative and other Neurological Disorders
. Verarbeitet und übermittelt durch Thomson Reuters ONE.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
Six Presentations at the 7th International Meeting on Metabotropic Glutamate
Receptors
Geneva, Switzerland, October 3, 2011 - Addex Pharmaceuticals (SIX:ADXN), a
leading biopharmaceutical company pioneering allosteric modulation-based drug
discovery and development, announced today that its scientists will present data
on multiple metabotropic glutamate receptor (mGluR) allosteric modulator
programs, including small molecule modulators of mGluR subtypes 2, 4, 5 and 7.
Held every three years, the prestigious International Meeting on Metabotropic
Glutamate Receptors, in Italy, brings together the world's leading researchers
in this field.
"These six presentations represent our continued success in addressing the
elusive mGluR targets and re-affirm our leadership position in addressing
important previously undruggable targets with oral small molecule allosteric
modulators," said Bharatt Chowrira, CEO of Addex. "Our advances in this field
are further illustrated by two lead products targeting mGluR5 and mGluR2,
dipraglurant-IR for Parkinson's disease levodopa-induced dyskinesia (PD-LID) and
ADX71149 for schizophrenia, respectively; both are currently in mid-stage
clinical testing and each has the potential to be first-in-class and best-in-
class in treating these serious neurological disorders."
Dipraglurant-IR, is an mGluR5 negative allosteric modulator, or NAM, which is in
Phase IIa testing for PD-LID. Top-line data are expected to be reported in the
first half of 2012. Addex partner Janssen Pharmaceuticals Inc. is developing
ADX71149, an mGluR2 positive allosteric modulator, or PAM, currently in Phase
IIa testing for the treatment of schizophrenia.
Glutamate, like dopamine and serotonin, is one of the major neurotransmitters in
the brain and other parts of the central nervous system. Because of their
importance, each of the many glutamate-specific receptors, including all eight
subtypes of mGluRs, has been the subject of intense research and drug discovery
efforts for more than 20 years. But, despite ever increasing knowledge about
their role in various neurologic disorders, the industry has struggled to
identify compounds that can selectively differentiate between the various
glutamate receptor subtypes using conventional small molecule discovery
techniques. In contrast, allosteric modulators have achieved excellent
selectivity for each mGluR subtype. This is because the allosteric binding sites
are less conserved compared to the receptor's active site, which is the binding
site for the body's natural activators (i.e. endogenous ligands) and
conventional small molecule drugs.
"At Addex, we have developed a proprietary allostery-biased library and highly
sensitive HTS screening systems tailored for discovery of selective and potent
allosteric modulators. In short, by industrializing the process of discovering
allosteric modulators, we are addressing an important bottleneck in small
molecule drug discovery that has hindered drug developers for decades and has
resulted in a growing number of undruggable validated targets," said Dr. Sonia
Poli, Head of CNS and Non-Clinical Development at Addex. "We believe these
orally bioavailable small molecules are able to exert exquisite selectivity at
the receptor subtype level and have the potential to be optimized into drugs
with the fine-tuned control needed to address major CNS disorders such as
schizophrenia, Parkinson's and Alzheimer's diseases, as well as non-CNS
indications."
Oral Presentations
Thursday, October 6, 4.30 - 4.55 pm
Selective mGluR2 negative allosteric modulators for the treatment of cognitive
deficits associated with Alzheimer's disease
Friday, October 7, 10.05 - 10.30 am
Anti-parkinsonian and anti-dyskinetic effects of dipraglurant (ADX48621), a
novel mGluR5 negative allosteric modulator in clinical development
Friday, October 7, 1.25 - 1.50 pm
Novel metabotropic glutamate receptor 4 (mGluR4) allosteric potentiators for the
treatment of Parkinson's disease and anxiety
Poster Presentations
Wednesday, October 5 from 20.00 to 23.00 in the Pharmacology session
Discovery and characterization of novel metabotropic glutamate receptor 4
(mGluR4) allosteric potentiators
Wednesday, October 5 from 20.00 to 23.00 in the Pharmacology session
Identification, synthesis and SAR investigation of a series of novel
metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators
Wednesday, October 5 from 20.00 to 23.00 in the Psychiatric Disorders session
Development of novel metabotropic glutamate receptor 7 (mGluR7) negative
allosteric modulators for treatment of anxiety disorders
Addex Pharmaceuticals (www.addexpharma.com) discovers and develops an emerging
class of small molecule drugs, called allosteric modulators, which have the
potential to be more specific and confer significant therapeutic advantages over
conventional "orthosteric" small molecule or biological drugs. The Company uses
its proprietary discovery platform to address receptors and other proteins that
are recognized as attractive targets for modulation of important diseases with
unmet medical needs. The Company's two lead products are being investigated in
Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative
allosteric modulator or NAM) is being developed by Addex to treat Parkinson's
disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive
allosteric modulator or PAM) is being developed by our partner Janssen
Pharmaceuticals, Inc., to treat schizophrenia. Addex also is advancing several
preclinical programs including: GABA-BR PAM for pain, overactive bladder and
other disorders; mGluR4 PAM for Parkinson's, anxiety and other diseases; GLP1R
PAM for type 2 diabetes; mGluR2 NAM for treating Alzheimer's disease and
depression; and FSHR/LHR NAM for sex hormone dependent tumors & reproductive
system disorders. In addition, Addex has discovery programs to identify
allosteric modulators of: receptor tyrosine kinase (RTK) superfamily, including
TrkB PAM for treating neurodegenerative diseases (e.g. Alzheimer's, Parkinson's
and Huntington's diseases); and TNF receptor superfamily, including TNFR1 NAM
for inflammation (e.g. rheumatoid arthritis) and other diseases.
Chris Maggos
Business Development & Communication
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos(at)addexpharma.com
Disclaimer: The foregoing release may contain forward-looking statements that
can be identified by terminology such as "not approvable", "continue",
"believes", "believe", "will", "remained open to exploring", "would", "could",
or similar expressions, or by express or implied discussions regarding Addex
Pharmaceuticals Ltd, its business, the potential approval of its products by
regulatory authorities, or regarding potential future revenues from such
products. Such forward-looking statements reflect the current views of Addex
Pharmaceuticals Ltd regarding future events, future economic performance or
prospects, and, by their very nature, involve inherent risks and uncertainties,
both general and specific, whether known or unknown, and/or any other factor
that may materially differ from the plans, objectives, expectations, estimates
and intentions expressed or implied in such forward-looking statements. Such may
in particular cause actual results with allosteric modulators of mGluR2,
mGluR4,mGluR5, GABABR, FSHR/LHR, GLP1R, TNFR1, RTK, TrkB or other therapeutic
targets to be materially different from any future results, performance or
achievements expressed or implied by such statements. There can be no guarantee
that allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR, FSHR/LHR, GLP1R,
TNFR1, RTK, TrkB or other therapeutics targets will be approved for sale in any
market or by any regulatory authority. Nor can there be any guarantee that
allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR, FSHR/LHR, GLP1R,
TNFR1, RTK, TrkB or other therapeutic targets will achieve any particular levels
of revenue (if any) in the future. In particular, management's expectations
regarding allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR, FSHR/LHR,
GLP1R, TNFR1, RTK, TrkB or other therapeutic targets could be affected by, among
other things, unexpected actions by our partners, unexpected regulatory actions
or delays or government regulation generally; unexpected clinical trial results,
including unexpected new clinical data and unexpected additional analysis of
existing clinical data; competition in general; government, industry and general
public pricing pressures; the company's ability to obtain or maintain patent or
other proprietary intellectual property protection. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those anticipated, believed,
estimated or expected. Addex Pharmaceuticals Ltd is providing the information in
this press release as of this date and does not undertake any obligation to
update any forward-looking statements contained in this press release as a
result of new information, future events or otherwise, except as may be required
by applicable laws.
--- Ende der Mitteilung ---
Addex Pharmaceuticals
12, chemin des Aulx Plan-les-Ouates; Geneva Schweiz
ISIN: CH0029850754;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Addex Pharmaceuticals via Thomson Reuters ONE
[HUG#1551607]
Relevante Links: Addex Therapeutics Ltd